Comprehensive medication guide to Bexagliflozin including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
Most Medicare Part D and commercial plans do not include bexagliflozin on formulary. When covered, it is typically classified as non-preferred brand with prior authorization required. Some PBMs like Scripius have added it as a preferred SGLT2 agent. Cash pay through partner pharmacies is usually the more cost-effective option.
Estimated Cash Pricing
$49.85/month at Cost Plus Drugs; $47.75/month at DiRx; approximately $69/month at Marley Drug. Retail list price without a partner pharmacy is approximately $400+ per 30-day supply.
Medfinder Findability Score
50/100
Summarize with AI
On this page
Bexagliflozin, sold under the brand name Brenzavvy, is a prescription medication approved by the FDA on January 23, 2023. It is manufactured by TheracosBio and belongs to the SGLT2 inhibitor drug class — the same class as Jardiance (empagliflozin), Farxiga (dapagliflozin), and Invokana (canagliflozin).
It is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not approved for type 1 diabetes, heart failure, or chronic kidney disease without diabetes.
Bexagliflozin is available only in one strength — 20 mg oral tablets — taken once daily in the morning with or without food. TheracosBio launched it at a dramatically lower price than other SGLT2 inhibitors: approximately $47–$50/month through partner pharmacies, compared to $500–$550/month for Jardiance or Farxiga.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Bexagliflozin works by selectively inhibiting SGLT2 (sodium-glucose co-transporter 2), a protein located in the proximal convoluted tubule of the kidney. Normally, SGLT2 reabsorbs approximately 90% of filtered glucose back into the bloodstream. By blocking this transporter, bexagliflozin causes excess glucose to remain in the urine and be excreted from the body — a process called glycosuria.
This mechanism lowers blood glucose without relying on insulin, making it effective even in advanced type 2 diabetes. Because it causes the body to excrete glucose (calories) in urine, it also produces modest weight loss (~6 lbs over 48 weeks) and blood pressure reduction (~2–3 mmHg systolic).
Bexagliflozin is primarily metabolized by UGT1A9 with a half-life of approximately 12 hours. It is approximately 93% protein-bound and has an apparent volume of distribution of 262 liters. The drug begins working within 24 hours of the first dose, with peak A1C lowering assessed at 24 weeks.
20 mg — tablet
Once-daily oral tablet taken in the morning, with or without food. Do not crush or chew. Only available strength.
Bexagliflozin is not listed on the FDA Drug Shortage Database. There is no manufacturing shortage. However, it is not stocked at most major chain pharmacies (CVS, Walgreens, Rite Aid) because TheracosBio launched it through a direct-to-consumer model. This makes it harder to find than other SGLT2 inhibitors at standard retail pharmacies.
The drug is reliably available through online partner pharmacies (Cost Plus Drugs at $49.85/month, DiRx at $47.75/month, Marley Drug at ~$69/month), Publix pharmacies in select southeastern US locations, and IPC-member independent pharmacies nationwide. Distribution has steadily expanded since launch in July 2023.
If you're having trouble locating bexagliflozin, medfinder calls pharmacies in your area to check which ones can fill your prescription — saving you hours of phone calls.
Bexagliflozin (Brenzavvy) is not a controlled substance and has no DEA scheduling. Any licensed prescriber authorized to treat type 2 diabetes can prescribe it, with no special DEA number or additional certification required.
Endocrinologists
Primary care physicians (internal medicine, family medicine)
Nurse practitioners (NPs)
Physician assistants (PAs)
Cardiologists (may prescribe for patients with T2DM and CV disease)
Nephrologists (may prescribe for patients with T2DM and CKD)
Bexagliflozin can be prescribed via telehealth in most US states. Because it is not a controlled substance, no in-person visit is required for the initial prescription. Providers can e-prescribe directly to Cost Plus Drugs or DiRx for convenient home delivery to patients.
No. Bexagliflozin (Brenzavvy) is not a controlled substance. The DEA has not scheduled it, and there are no special prescribing restrictions based on controlled substance status.
As a non-controlled prescription medication, bexagliflozin can be prescribed by any licensed prescriber, including primary care physicians, nurse practitioners, and physician assistants. It can be prescribed via telehealth in most states. Refills can be phoned, faxed, or electronically transmitted — there are no restrictions on early refills based on controlled substance status.
Urinary tract infections (UTIs)
Genital yeast infections (mycotic infections)
Increased urination (polyuria)
Dehydration (volume depletion)
Hypoglycemia (when used with insulin or sulfonylureas)
Diabetic ketoacidosis (DKA) — even at near-normal blood glucose levels
Fournier's gangrene (necrotizing fasciitis of the genitals/perineum)
Serious urinary tract infections (urosepsis, pyelonephritis)
Lower limb amputation risk (especially in patients with peripheral vascular disease)
Acute kidney injury
Hypotension (symptomatic low blood pressure)
Hypersensitivity reactions (anaphylaxis, angioedema)
Know what you need? Skip the search.
Jardiance (empagliflozin)
Most prescribed SGLT2 inhibitor; FDA-approved for T2DM, heart failure, CKD, and cardiovascular risk reduction. Widely stocked at all pharmacies. ~$550/month list price; manufacturer savings card available.
Farxiga (dapagliflozin)
SGLT2 inhibitor approved for T2DM, heart failure, and CKD. Generic dapagliflozin available as of 2025. ~$500/month brand list price.
Invokana (canagliflozin)
First FDA-approved SGLT2 inhibitor (2013). Indicated for T2DM and cardiovascular risk reduction. Note higher amputation risk data vs. other SGLT2s.
Steglatro (ertugliflozin)
SGLT2 inhibitor approved for type 2 diabetes only. Available in 5 mg and 15 mg tablets. Smaller market presence than Jardiance or Farxiga.
Prefer Bexagliflozin? We can find it.
Insulin and insulin analogs
moderateIncreases hypoglycemia risk — consider lowering insulin dose when starting bexagliflozin. Monitor blood glucose closely.
Sulfonylureas (glimepiride, glipizide, glyburide)
moderatePharmacodynamic synergism increases hypoglycemia risk. Lower sulfonylurea dose may be required.
UGT1A9 inducers (carbamazepine, rifampin, phenytoin)
moderateSignificantly reduces bexagliflozin plasma levels and efficacy. Consider adding another antihyperglycemic agent or switching SGLT2 inhibitors.
Diuretics (furosemide, hydrochlorothiazide)
moderateAdditive volume depletion and hypotension risk. Monitor for dehydration and electrolyte imbalances.
ACE inhibitors and ARBs
moderateAdditive renal hemodynamic effects. Monitor kidney function and blood pressure periodically.
NSAIDs (ibuprofen, naproxen)
moderateIncreased acute kidney injury risk, especially with concurrent volume depletion. Consider acetaminophen as alternative.
Beta-blockers
minorMay mask tachycardia associated with hypoglycemia. Sweating remains an unmasked warning sign.
Bexagliflozin represents a meaningful step toward making SGLT2 inhibitor therapy accessible to more patients with type 2 diabetes. At approximately $47–$50/month through partner pharmacies, it offers the same glucose-lowering mechanism as Jardiance and Farxiga at a fraction of the cost — without income requirements, copay card enrollments, or insurance battles.
The main challenge is access: because it's not stocked at most chain pharmacies, patients need to know where to look. Cost Plus Drugs, DiRx, Marley Drug, Publix pharmacies, and IPC-affiliated independent pharmacies are your best bets. Distribution continues to expand.
If you're having trouble finding bexagliflozin in stock, medfinder can help. We call pharmacies in your area to check availability so you don't have to spend hours on hold. Simply enter your medication, dose, and location to get started.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini